Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
EPS (Diluted)
Sonoma Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
EPS (Diluted)
$0
|
CAGR 3-Years
23%
|
CAGR 5-Years
49%
|
CAGR 10-Years
36%
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$16
|
CAGR 3-Years
43%
|
CAGR 5-Years
25%
|
CAGR 10-Years
12%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$3
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$0
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-20%
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$0
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-21%
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$5
|
CAGR 3-Years
-5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
3%
|
See Also
What is Sonoma Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-0.5
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's EPS (Diluted) amounts to -0.5 USD.
What is Sonoma Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
36%
Over the last year, the EPS (Diluted) growth was 79%. The average annual EPS (Diluted) growth rates for Sonoma Pharmaceuticals Inc have been 23% over the past three years , 49% over the past five years , and 36% over the past ten years .